Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-15
2007-05-15
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S236000
Reexamination Certificate
active
10780441
ABSTRACT:
Disclosed herein is compound 1or a pharmaceutically acceptable salt, or a prodrug thereof. Compound 1 is useful for treating or preventing a variety of diseases or conditions. Results presented herein also demonstrate that Compound 1 is a prostaglandin D2antagonist, and as such is useful in the treatment or prevention of prostaglandin D2mediated conditions or diseases.A method comprising administering a prostaglandin D2antagonist to a mammal suffering from a disease or condition selected from the group consisting of the gastrointestinal tract disorders or diseases, hyperalgesia, allodynia, abdominal cramping, glaucoma, ocular hypertension, and ocular hypotension is also disclosed herein.Pharmaceutical compositions and products comprising compound 1 are also disclosed.
REFERENCES:
patent: 4808608 (1989-02-01), Guindon et al.
patent: 5491254 (1996-02-01), Sato et al.
patent: 6369082 (2002-04-01), Lacombe et al.
patent: 6369089 (2002-04-01), Burk et al.
patent: 6407250 (2002-06-01), Burk et al.
patent: 6410583 (2002-06-01), Labelle et al.
patent: 2001/0051624 (2001-12-01), Jones
patent: 2003/0055077 (2003-03-01), Jones
patent: 2003/0158246 (2003-08-01), Berthelette, et al.
patent: 837 0582 (1998-04-01), None
patent: WO 98/25919 (1998-06-01), None
patent: WO 99/62555 (1999-09-01), None
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Boie, Y, et al., “Molecular cloning and characterization of the human prostanoid DP receptor”Journal of Biological Chemistry, vol. 270, No. 32, Aug. 11, 1995, pp. 18910-18916.
Breyer, M.D., et al., “Functional and molecular aspects of renal prostaglandin receptors”J. Am. Soc.Nephrol, 1996;7:8-17.
Coleman, R.A., “Prostanoid Receptors”Eicosanoids From Biotechnology to Therapeutic Applications, Plenum Press, 1996, Chp. 14, 137-154.
Darius, H., et al., Inhibition of human platelets and polymorphonuclear neutrophils by the otent and metabolically stable prostaglandin D2 analog ZK 118.182European Journal of Pharm, 258(1994) 207-213.
Giles, H., et al., The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel selective and potent competitive antagonist,Br. J. Pharmacol., (1989), 96, 291-300.
Hirai, H, et al., “Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2”,J. Exp. Med, The Rockfeller Univ. Press, vol. 192, No. 2, Jan. 15, 2001, 255-261.
Ichikawa, A., “Molecular aspects of the structures and functions of the prostaglandin E receptors”,J of Lipid Mediators and Cell Signalling, 14 (1996) 83-87.
Matsuoka, T., et al., “Prostaglandin D2 as a Mediator of allergic asthma”,Sciencevol. 287, Mar. 17, 2000, pp. 2013-2017.
Negishi, M. et al., “Prostanoid receptors and their biological actions”Prog. Lipid Res.vol. 32, No. 4, pp. 417-434,1993.
Ney, P., et al., GD 2 and its mimetic ZK 110.841 are potent inhibitors of receptor-medicated activation of human neutrophils,Eicosanoids, 1991 4:21-28.
Pons, F., et al., “Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue ZK. 182”European Journal of Pharm, 261 (1994) 237-247.
Rangachari, P.K., et al., “Effects of a selective DP receptor agonist (BW 245C) and antagonists (BW A868C) on the canine colonic epithelium : an argument for a different DP receptor”,The Journal of Pharmacology and experimental therapeutics, vol. 275, No. 2, 611-617 (1995).
Tsuri, T., et al, “Bicyclo [2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane Derivatives: orally active, potent and selective prostaglandin D2 receptor antagonists”J. Med. Chem, 1997, 40, 3504-3507.
Wright, D.H., et al., “A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor”,European Journal of Pharmacology, 377 (1999) 101-115.
Wright, D.H., et al., “Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist”,British J. of Pharm. (1998)123,1317-1324.
Burk Robert M.
Donde Yariv
Krauss Achim H.
Woodward David
Allergan Inc.
Johnson Brent A.
Stockton Laura L.
Voet Martin A.
LandOfFree
Prostaglandin D2 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin D2 antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin D2 antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801903